GSK563

GSK563 is a potent GVIA iPLA2 inhibitor (XI (50) 0.0000021, IC50 1 nM) . GSK563 is 22 000 times more active against GVIA iPLA2 than GIVA cPLA2. It was found to reduce β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes.